ArticleNature communications2021
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 54 citations in OpenAlex.
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- SARS-CoV-2 virus infection ofbioRxiv : the preprint server for biology · 2026Article
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates.Nature communications · 2025Article
- Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants.Journal of nanobiotechnology · 2025Article
- Viral Rebound After Antiviral Treatment: A Mathematical Modeling Study of the Role of Antiviral Mechanism of Action.Interdisciplinary sciences, computational life sciences · 2024Article
- Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.Journal of virology · 2024Article
- Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques.Communications medicine · 2024Article
- Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.PLoS pathogens · 2024Article
- Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual.iScience · 2023Article
- Article
- Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.bioRxiv : the preprint server for biology · 2023Article
- Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates.PLoS computational biology · 2023Article
- Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates.PLoS pathogens · 2023Article
- Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.Heliyon · 2023Article
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.Pharmaceutics · 2023Review
- Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses.iScience · 2023Article
- SARS-CoV-2-related bat virus behavior in human-relevant models sheds light on the origin of COVID-19.EMBO reports · 2023Article
- Article
- Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
- Update of
Authors and funding
51 authors at 9 institutions in 4 countries.
Pauline Maisonnasse *Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0002-0555-207X
Yoann Aldon *Departments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.ORCID 0000-0001-9831-9391
Aurélien MarcUniversité de Paris, INSERM, IAME, Paris, France.
Romain MarlinUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0001-8932-0171
Nathalie Dereuddre-BosquetUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0001-6682-6313
Natalia A KuzminaDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0001-6650-9369
Alec W FreynDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-5963-8995
Jonne L SnitselaarDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Antonio GonçalvesUniversité de Paris, INSERM, IAME, Paris, France.ORCID 0000-0002-8759-2429
Tom G CanielsDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.ORCID 0000-0001-9580-157X
Judith A BurgerDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Meliawati PonimanDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Ilja BontjerDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.ORCID 0000-0002-8406-7733
Virginie ChesnaisLife and Soft, Le Plessis-Robinson, France.
Ségolène DiryLife and Soft, Le Plessis-Robinson, France.
Anton IershovLife and Soft, Le Plessis-Robinson, France.
Adam J RonkDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0001-8202-9154
Sonia JangraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Philip J M BrouwerDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Tom P L BijlDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Jelle van SchootenDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.ORCID 0000-0002-5202-355X
Mitch BrinkkemperDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Hejun LiuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Meng YuanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-9754-4503
Chad E MireGalveston National Laboratory, Galveston, TX, USA.ORCID 0000-0001-7596-1808
Mariëlle J van BreemenDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Vanessa ContrerasUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Thibaut NaninckUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.ORCID 0000-0002-6261-6412
Julien LemaîtreUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Nidhal KahlaouiUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Francis RelouzatUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Catherine ChaponUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Raphaël Ho Tsong FangUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France.
Charlene McDanalDuke Human Vaccine Institute & Department of Surgery, Durham, NC, USA.
Mary Osei-TwumNexelis, Laval, Québec, Canada.
Natalie St-AmantNexelis, Laval, Québec, Canada.
Luc GagnonNexelis, Laval, Québec, Canada.
David C MontefioriDuke Human Vaccine Institute & Department of Surgery, Durham, NC, USA.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-6469-2419
Eric GinouxLife and Soft, Le Plessis-Robinson, France.
Godelieve J de BreeInternal Medicine of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6551-1827
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3156-3132
Lynda CoughlanDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-9880-6560
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0002-0342-4824
Sylvie van der WerfMolecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Université de Paris, Paris, France.ORCID 0000-0002-1148-4456
Jérémie GuedjUniversité de Paris, INSERM, IAME, Paris, France.ORCID 0000-0002-5534-5482
Rogier W SandersDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands. r.w.sanders@amsterdamumc.nl.
Marit J van GilsDepartments of Medical Microbiology of the Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands. m.j.vangils@amsterdamumc.nl.
Roger Le GrandUniversité Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, Paris, France. roger.le-grand@cea.fr.ORCID 0000-0002-4928-4484
Inserm · FRAmsterdam University Medical Centers · NLIcahn School of Medicine at Mount Sinai · USAR2i · FRGalveston College · USScripps Research Institute · USCentre National de la Recherche Scientifique · FRCornell University · USUniversity of Maryland, Baltimore · US
Funding
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MExosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectorsR21AI157606 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COUGHLAN, LYNDA · 2020 to 2020
$425kNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R21 AI157606NIAID NIH HHS U19 AI135972
Abstract
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.
Indexed as
COVID-19 Drug TreatmentAngiotensin-Converting Enzyme 2AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsCOVID-19Disease Models, AnimalDrug Evaluation, PreclinicalFemaleHumansLungMacaca fascicularisMaleMesocricetusMiceACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntiviral AgentsCOVA1-18
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.